Market Cap 1.70B
Revenue (ttm) 1.14M
Net Income (ttm) -88.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,722.81%
Debt to Equity Ratio 0.00
Volume 1,658,200
Avg Vol 990,236
Day's Range N/A - N/A
Shares Out 76.22M
Stochastic %K 97%
Beta 1.24
Analysts Strong Sell
Price Target $62.38

Latest News on CGON

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Apr 2, 2025, 12:32 PM EDT - 24 days ago

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)


CG Oncology Announces Pricing of Public Offering

Dec 12, 2024, 8:19 PM EST - 4 months ago

CG Oncology Announces Pricing of Public Offering


CG Oncology Announces Proposed Public Offering

Dec 11, 2024, 6:17 AM EST - 4 months ago

CG Oncology Announces Proposed Public Offering


CG Oncology: Promising Data, But Looks Expensive

Aug 26, 2024, 10:34 AM EDT - 8 months ago

CG Oncology: Promising Data, But Looks Expensive


CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 9, 2024, 9:19 AM EDT - 10 months ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer


Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA


Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 26, 2024, 11:50 AM EST - 1 year ago

Biotech's First IPO of 2024 Popped 96%. What It Means.


CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 1:46 PM EST - 1 year ago

CG Oncology valued at $1.75 bln in strong market debut